[ad_1]
The British laboratory AstraZeneca announced on Monday that the COVID-19 vaccine, which it is developing jointly with the University of Oxford, is 70% effective in preventing the disease.
The laboratory explained that they are temporary results of clinical trials conducted on a large scale in Great Britain and Brazil.
AstraZeneca principal investigator Andrew Pollard said the scientists are happy with the results, noting that the researchers found that if people were given half a dose followed by a full dose, rather than two full doses, the rate of prevention increases to 90 percent.
And Pollard said: “These results show that we have an effective vaccine that will save many lives.”
This vaccine is less convincing than the Pfizer / Biontech and Our Directors vaccines, which are more than 90% effective and approach 95%.
The success rate of the vaccine that the American company “Pfizer” and the German emerging corona virus “Biontech” is the highest of all the vaccines tested in the last clinical stages so far, and the experts say it is a great achievement in the race to the end of the pandemic.
The final analysis of the experiments conducted with the vaccine comes after just one week of initial results from the Pfizer / Biontech vaccine, which showed the vaccine to be more than 90 percent effective, while Moderna subsequently released preliminary data. about their vaccine showing its effectiveness of 94.5 percent.
And it turns out that the “Pfizer” and “Biontech” vaccines have achieved 94 percent effectiveness among people over 65, which experts described as very important at a time when the virus is spreading around the world. with record cases.
The Moderna experimental vaccine ranks second in effectiveness, as the American company Moderna revealed that its experimental vaccine is 94.5 percent effective in preventing Corona virus, based on temporary data from clinical trials that reached a stage late, so the American company became the second developer. Which provides results that far exceeded expectations, after Pfizer and its partner, Biontech.
The European Union has been holding talks with “modern” on its experimental vaccine for the virus Corona, to the least since last July, according to “Reuters”.
Although the two vaccines, Pfizer / Biontec and Moderna, are more effective than the one produced by the University of Oxford in terms of effectiveness, the latter is distinguished from them by the fact that it does not need to be stored at low temperatures, as is the case. of the first two vaccines.
[ad_2]
